Leonardo Viana Nicacio - 16 Aug 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRBP
Reported as of: 16 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2026, 16:30:04 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, attorney-in-fact for Leonardo Nicacio

Key filing fact

Leonardo Viana Nicacio filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 17 Aug 2026.

Key facts

This page summarizes Leonardo Viana Nicacio's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2026, 16:30.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002064901 Primary reporting owner

Nicacio Leonardo Viana

Relationship: Chief Medical Officer
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, attorney-in-fact for Leonardo Nicacio
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value
Shares: +58,333
Change %
Price: $0.000000^*
Shares after: 58,333
Date: 16 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +191,676
Change %
Price: $0.000000^*
Shares after: 191,676
Date: 16 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 191,676
Exercise price: $10.09
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On August 16, 2026, the Reporting Person was granted 58,333 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on August 16, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardee's termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

Footnote F2

This amount includes 58,333 unvested RSUs granted on August 16, 2026.

Footnote F3

This option award was made in accordance with the terms of the issuer's 2026 Inducement Award Plan. 25% of the option vests on August 3, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 3, 2027.